Shaojun Zhang

List of Publications by Year
in descending order

33 papers	4,269 citations	516710 16 h-index	501196 28 g-index
36 all docs	36 docs citations	36 times ranked	8538 citing authors

#	Article	IF	Citations
1	B cells and tertiary lymphoid structures promote immunotherapy response. Nature, 2020, 577, 549-555.	27.8	1,421
2	Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas. Cell Reports, 2018, 23, 239-254.e6.	6.4	801
3	Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma. Nature Medicine, 2018, 24, 1649-1654.	30.7	592
4	Characteristics of anti-CD19 CAR T cell infusion products associated with efficacy and toxicity in patients with large B cell lymphomas. Nature Medicine, 2020, 26, 1878-1887.	30.7	321
5	Metabolic reprogramming toward oxidative phosphorylation identifies a therapeutic target for mantle cell lymphoma. Science Translational Medicine, 2019, 11, .	12.4	161
6	Single-cell dissection of intratumoral heterogeneity and lineage diversity in metastatic gastric adenocarcinoma. Nature Medicine, 2021, 27, 141-151.	30.7	134
7	Epithelial memory of inflammation limits tissue damage while promoting pancreatic tumorigenesis. Science, 2021, 373, eabj0486.	12.6	99
8	Multiplex profiling of peritoneal metastases from gastric adenocarcinoma identified novel targets and molecular subtypes that predict treatment response. Gut, 2020, 69, 18-31.	12.1	94
9	Longâ€term outcomes and mutation profiling of patients with mantle cell lymphoma (MCL) who discontinued ibrutinib. British Journal of Haematology, 2018, 183, 578-587.	2.5	81
10	9p21 loss confers a cold tumor immune microenvironment and primary resistance to immune checkpoint therapy. Nature Communications, 2021, 12, 5606.	12.8	76
11	Poor Response to Neoadjuvant Chemotherapy Correlates with Mast Cell Infiltration in Inflammatory Breast Cancer. Cancer Immunology Research, 2019, 7, 1025-1035.	3.4	70
12	Efficacy of venetoclax in high risk relapsed mantle cell lymphoma (<scp>MCL</scp>) â€•outcomes and mutation profile from venetoclax resistant <scp>MCL</scp> patients. American Journal of Hematology, 2020, 95, 623-629.	4.1	54
13	Genomic profiles and clinical outcomes of de novo blastoid/pleomorphic MCL are distinct from those of transformed MCL. Blood Advances, 2020, 4, 1038-1050.	5.2	43
14	Longitudinal single-cell profiling reveals molecular heterogeneity and tumor-immune evolution in refractory mantle cell lymphoma. Nature Communications, 2021, 12, 2877.	12.8	35
15	A pilot study of pembrolizumab in smoldering myeloma: report of the clinical, immune, and genomic analysis. Blood Advances, 2019, 3, 2400-2408.	5.2	28
16	Integrated genomic profiling and modelling for risk stratification in patients with advanced oesophagogastric adenocarcinoma. Gut, 2021, 70, 2055-2065.	12.1	24
17	Frontline Treatment with Ibrutinib Plus Rituximab (IR) Followed By Short Course R-Hypercvad/MTX Is Extremely Potent and Safe in Patients (age â‰¥ 65 years) with Mantle Cell Lymphoma (MCL) - Results of Phase-II Window-1 Clinical Trial. Blood, 2019, 134, 3987-3987.	1.4	12
18	Genetically Defined Metabolic Targets Overcome Ibrutinib Resistance in Mantle Cell Lymphoma. Blood, 2019, 134, 395-395.	1.4	8

#	Article	IF	Citations
19	Integrated transcriptomicâ€“genomic tool Texomer profiles cancer tissues. Nature Methods, 2019, 16, 401-404.	19.0	7
20	Outcomes of relapsed mantle cell lymphoma patients after discontinuing acalabrutinib. American Journal of Hematology, 2021, 96, E137-E140.	4.1	6
21	Targeting PI3K and PLK1 to Overcome Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma. Blood, 2019, 134, 4062-4062.	1.4	6
22	Computational immune infiltration analysis of pediatric highâ€grade gliomas (pHGGs) reveals differences in immunosuppression and prognosis by tumor location. Computational and Systems Oncology, 2021, 1, e1016.	1.5	5
23	Outcomes, Causes of Discontinuation and Mutation Profile of Patients with Mantle Cell Lymphoma Who Progressed on Acalabrutinib. Blood, 2018, 132, 4151-4151.	1.4	4
24	Clinical and Genomic Characteristics in De Novo Blastoid/Pleomorphic (dnMCL) and Transformed Blastoid/Pleomorphic (t-MCL) Mantle Cell Lymphoma (MCL) in the Ibrutinib Era: Comprehensive Analysis of 168 Patients. Blood, 2018, 132, 1599-1599.	1.4	2
25	Outcomes of Acalabrutinib Failures in Relapsed Mantle Cell Lymphoma. Blood, 2020, 136, 9-10.	1.4	2
26	Oncogenic MALT1 Promotes Cell Survival and Mediates Ibrutinib Resistance and Ibrutinib-Venetoclax Resistance in Mantle Cell Lymphoma. Blood, 2020, 136, 18-18.	1.4	2
27	Ibrutinib-Resistant Mantle Cell Lymphoma Undergoes Metabolic Reprogramming Towards Oxphos. Blood, 2018, 132, 41-41.	1.4	0
28	Unravelling the Heterogeneity of Mantle Cell Lymphoma Ecosystem By Single Cell RNA Sequencing. Blood, 2018, 132, 4118-4118.	1.4	0
29	Analysis of Factors Predictive of Risk of Transformation and Time to Transformation in Patients (pts) with Mantle Cell Lymphoma - Cohort Study of 369 Patients. Blood, 2019, 134, 1526-1526.	1.4	0
30	Pdox Models Empower Preclinical Drug Evaluation and Mechanistic Studies Via Faithful Recapitulation of the Pathology, Complex Heterogeneity, Genetic-Transcriptomic Landscape, and Therapeutic Response of Mantle Cell Lymphoma. Blood, 2019, 134, 3974-3974.	1.4	0
31	Transcriptomic Heterogeneity and Clonal Evolution Associated with Therapeutic Resistance in Mantle Cell Lymphoma Revealed By Single Cell RNA-Seq. Blood, 2019, 134, 5217-5217.	1.4	0
32	Xeno-MCL: Genomic, Transcriptomic and Pathologic Landscape Associated with Disease Progression, Clonal Evolution and Tissue Tropism in Patient-Derived Xenografts of Mantle Cell Lymphoma. Blood, 2020, 136, 20-20.	1.4	0
33	Single Cell Transcriptomic Evolution and Resistance Mechanisms of BTK and BCL-2 Inhibition in Mantle Cell Lymphoma. Blood, 2020, 136, 33-34.	1.4	0